Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oxford Pre-cancerous Lymphoproliferative Disorders Study (OxPLoreD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04023747
Recruitment Status : Recruiting
First Posted : July 17, 2019
Last Update Posted : February 21, 2020
Sponsor:
Collaborator:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
University of Oxford

Brief Summary:
OxPLoreD is an observational cohort study to identify clinical, genomic and immunological predictive markers of progression to malignant disease. Open to individuals diagnosed in the last 3 years with high count MBL, Binet Stage A CLL, Immunoglobulin G/A/M (IgG, IgA, IgM) MGUS, asymptomatic WM not requiring treatment and smouldering myeloma not requiring treatment.

Condition or disease
Pre-cancerous Lymphoproliferative Disorders

Detailed Description:

The purpose of the study is to monitor patients with early stage lymphoproliferative disorders not meeting criteria for treatment, including early stage Chronic Lymphocytic Leukaemia (CLL), Monoclonal B-cell Lymphocytosis (MBL), Monoclonal Gammopathy of Uncertain Significance (MGUS), asymptomatic Waldenstroms Macroglobulinaemia (WM) and Smouldering Myeloma (SM).

Each of these disorders has a pre-cancerous phase when abnormalities can be seen in the blood, however treatment may not be required. A minority of people with early stage lymphoproliferative disorders will go on to need treatment for blood or bone marrow cancer.

Currently the investigators do not have a reliable way to predict which of these individuals with these disorders are more likely to develop a blood or bone marrow cancer. By studying a large group of individuals over time we hope to discover more about what factors might predict progression.The investigators may be able to identify markers which identify individuals who are more or less likely to develop blood or bone marrow cancer. These markers might be particular symptoms, gene changes called mutations or levels of particular molecules or cells in the blood or bone marrow. In the longer term this may enable us to identify those people who would benefit from certain types of treatment or from receiving treatment at an earlier stage and also to confidently reassure those who will never progress.

Patients will be studied for up to 5 years with blood, bone marrow and saliva samples taken at key time-points to help answer these questions. In addition to looking for these markers we will also collect information about:

  • What it is like to live with one of these conditions
  • How many people with these conditions develop other significant medical conditions, such as serious infections, thrombosis (blood clots) or other types of cancer.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1650 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Oxford Pre-cancerous Lymphoproliferative Disorders: Analysis and Interception Study
Actual Study Start Date : July 3, 2019
Estimated Primary Completion Date : July 2024
Estimated Study Completion Date : July 2026


Group/Cohort
Cohort 1
Participants with Monoclonal B-Cell Lymphocytosis or Asymptomatic Chronic Lymphocytic Leukaemia
Cohort 2
Participants with IgM Monoclonal Gammopathy or Asymptomatic Waldenstrom's Macroglobulinaemia
Cohort 3
Participants with IgA or IgG Monoclonal Gammopathy or Smouldering Myeloma



Primary Outcome Measures :
  1. The identification of predictive markers of progression to malignant disease [ Time Frame: Duration of the study (5 years) ]
    Relevant markers will be identified from the analysis of the clinical data in combination with the genomic and immunological data from the samples collected. The markers will be combined to produce a single probability risk score. The choice of relevant markers will be guided by emerging evidence and techniques under the guidance of the study scientific advisory board.


Secondary Outcome Measures :
  1. Patient reported outcome measures (PROM) via approved quality of life questionnaires. [ Time Frame: Duration of study (5 years) ]
    Analysis of approved questionnaires: EORTC CLL17

  2. To study other clinically significant events, not inevitably due to disease progression in this patient cohort [ Time Frame: Duration of study (5 years) ]
    Assessed by analysing suspected unexpected serious adverse reactions (SUSARs) reported

  3. Production of evidence-based standard of care guidelines for the monitoring and follow-up of patients with these pre-cancerous conditions [ Time Frame: Duration of study (5 years) ]
    The identification of relevant markers can be used to create guidelines for optimal monitoring of patients with these pre-cancerous conditions

  4. Patient reported outcome measures (PROM) via approved quality of life questionnaires. [ Time Frame: Duration of study (5 years) ]
    Analysis of approved questionnaires: EORTC NHL-LG20

  5. Patient reported outcome measures (PROM) via approved quality of life questionnaires. [ Time Frame: Duration of study (5 years) ]
    Analysis of approved questionnaires: EORTC QLQ-C30

  6. Patient reported outcome measures (PROM) via approved quality of life questionnaires. [ Time Frame: Duration of study (5 years) ]
    Analysis of approved questionnaires: EORTC QLQ-MY20


Biospecimen Retention:   Samples With DNA
Whole blood Plasma Urine Saliva Bone marrow aspirate


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The study targets three groups of pre-cancerous lymphoproliferative disorders
Criteria

Inclusion Criteria:

  1. Patients diagnosed within the previous three years with one of the following:

    1. High count monoclonal B-cell lymphocytosis (MBL) i.e. clonal B-cell population 0.5-4.9 109/L
    2. Rai Stage 0-2/ Binet Stage A or Stage B Chronic Lymphocytic Leukaemia not meeting the IWCLL criteria for treatment
    3. IgG or IgA Monoclonal Gammopathy of Uncertain Significance meeting one of the following criteria:

    i) IgA paraprotein >10g/L or

    ii) IgG paraprotein >15g/L or

    iii) IgA/IgG paraprotein below these cut-offs but kappa:lambda light chain ratio of

    • <0.1 to >3.0 (For OUH participants or sites with no pre-defined cut offs for high risk MGUS) or
    • within the cut off criteria of the local laboratory ranges for high risk MGUS

    iv) Patients not meeting the cut-offs defined in points i) to iii) but who are referred to secondary care e.g. due to general practitioner (GP) concern or for investigation of symptoms

    d. IgM Monoclonal Gammopathy of Uncertain Significance meeting one of the following criteria: i) IgM paraprotein >10g/L or

    ii) IgM paraprotein <10g/L and difference between the kappa and lambda light chains of >50mg/L

    iii) Patients not meeting the cut-offs defined in point i) and ii) but who are referred to secondary care e.g. due to GP concern or investigation of symptoms

    e) Asymptomatic smouldering Waldenstrom's Macroglobulinaemia not meeting the criteria for treatment f) Smouldering myeloma not meeting the criteria for treatment

  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2
  3. Age 16 years and over
  4. Sign written informed consent
  5. The patient is willing and able to comply with the protocol for the duration of the study and scheduled follow-up visits and examinations

Exclusion Criteria:

  1. Pregnant or breast-feeding women. Pregnant or breast-feeding women may be re-screened following delivery and/or cessation of breastfeeding, as appropriate
  2. Previous chemotherapy or immunotherapy for any haematological cancers
  3. Treatment with any other investigational agent, or participation in an interventional clinical trial within 28 days prior to enrolment.
  4. Patients in cohort 2 or 3 on anticoagulation for a diagnosis of pulmonary embolus or deep vein thrombosis within the last 3 months or with a mechanical heart valve or any other condition causing a significant risk of thromboembolism. Participants who are anticoagulated for atrial fibrillation are eligible, but will be asked to interrupt anticoagulation 3 days prior to bone marrow examination
  5. Other psychological, social or medical condition, physical examination finding or laboratory abnormality that the investigator considers would make the patient a poor study candidate or could interfere with protocol compliance or the interpretation of study results.
  6. Any other malignancy that requires active surgical or chemotherapeutic Patients on long term hormone therapies (e.g. Tamoxifen) are permitted to enrol at the discretion of investigator, after considering the overall clinical context
  7. Any significant concurrent medical resulting in life-expectancy (including but no limited to renal, Hepatic, haematological gastrointestinal, endocrine pulmonary neurological, cerebral or psychiatric disease
  8. For cohort 3: Any contraindication for MRI- presence of any metallic foreign body, eGFR <30 and allergy to gadolinium contrast

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04023747


Contacts
Layout table for location contacts
Contact: Steven Davis 01865 617087 octo-oxplored@oncology.ox.ac.uk

Locations
Layout table for location information
United Kingdom
Churchill Hospital, Oxford University Hospitals Trust Recruiting
Oxford, United Kingdom, OX3 7LE
Contact: Anna Schuh         
Sponsors and Collaborators
University of Oxford
Janssen Research & Development, LLC
Investigators
Layout table for investigator information
Principal Investigator: Anna Schuh University of Oxford
Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT04023747    
Other Study ID Numbers: OCTO_091
First Posted: July 17, 2019    Key Record Dates
Last Update Posted: February 21, 2020
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Oxford:
Monoclonal B-Cell Lymphocytosis
Asymptomatic Chronic Lymphocytic Leukaemia
IgM Monoclonal Gammopathy
Asymptomatic Waldenstrom's Macroglobulinaemia
Immunoglobulin A or G Monoclonal Gammopathy
Smouldering Myeloma
Pre-cancerous
Lymphoproliferative Disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoproliferative Disorders
Disease
Pathologic Processes
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases